z-logo
Premium
Cyclosporin in dermatology: A practical compendium
Author(s) -
Amber Tazein,
Tabassum Saadia
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13934
Subject(s) - medicine , dermatology , atopic dermatitis , pyoderma gangrenosum , tacrolimus , alopecia areata , psoriasis , adverse effect , granuloma annulare , medline , calcineurin , intensive care medicine , disease , pharmacology , surgery , transplantation , pathology , political science , law
Cyclosporine A (CYA) belongs to calcineurin inhibitor family, which has the ability to selectively suppress T cells. Owing to its immune‐modulatory effects, it had been in use for graft vs host diseases and organ transplant rejection for many years, but in dermatology, it was first approved for use in 1997 in the treatment of psoriasis. Other off‐label indications for skin diseases include atopic dermatitis, chronic spontaneous urticaria, lichen planus, pyoderma gangrenosum, alopecia areata, granuloma annulare, and several others. A thorough search of Medline‐PubMed database, Google Scholar, and Uptodate was performed for evidence‐based and peer‐reviewed information. We have summarized the use of cyclosporine in dermatological diseases with respect to its, dosage, safety considerations, and monitoring guidelines. Furthermore, brief overview of its pharmacology, drug interactions, use in pregnancy, and lactation has been discussed. Despite of its common adverse effects like nephrotoxicity and hypertension, cyclosporine offers good safety profile when used in skin diseases. Decision to start cyclosporine therapy is individualized and it should be based on analysis of risk vs benefit. Nevertheless, CYA is preferred over other immunosuppressants in dermatology because of early therapeutic response and less myelosupression. This article offers concise but detailed summary of this beneficial immune‐suppressive agent in skin diseases.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here